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To aid informed health sector decision-making, data from sufficient high quality economic evaluations must be
available to policy makers. To date, no known study has analysed the quantity and quality of available Iranian
economic evaluation studies. This study aimed to assess the quantity, quality and targeting of economic evaluation
studies conducted in the Iranian context.
The study systematically reviewed full economic evaluation studies (n = 30) published between 1999 and 2012 in
international and local journals. The findings of the review indicate that although the literature on economic
evaluation in Iran is growing, these evaluations were of poor quality and suffer from several major methodological
flaws. Furthermore, the review reveals that economic evaluation studies have not addressed the major health
problems in Iran.
While the availability of evidence is no guarantee that it will be used to aid decision-making, the absence of
evidence will certainly preclude its use. Considering the deficiencies in the data identified by this review, current
economic evaluations cannot be a useful source of information for decision makers in Iran. To improve the quality
and overall usefulness of economic evaluations we would recommend; 1) developing clear national guidelines for
the conduct of economic evaluations, 2) highlighting priority areas where information from such studies would be
most useful and 3) training researchers and policy makers in the calculation and use of economic evaluation data.
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Introduction
Economic evaluations identify, measure, value and com-
pare the cost and consequences of two or more alterna-
tive programs or interventions [1]. Economic evaluation
is commonly used as a decision tool in health care
systems where, due to resource constrains, policy-
makers have to choose between alternative activities
with different implications for resources allocation [2].
Iran is a middle-income country with a population of
76 million. In 2009, Iran had a Gross National Income
(GNI) per capita of US$ 10,250 and approximately 6% of
its gross domestic production (GDP) per capita is spent
on healthcare [3]. The constitution emphasizes the right
of access to the highest level of health for all citizens* Correspondence: h.haghparast-bidgoli@ucl.ac.uk
1Institute for Global Health, University College London, London, UK
Full list of author information is available at the end of the article
© 2014 Haghparast-Bidgoli et al.; licensee BioM
the Creative Commons Attribution License (ht
distribution, and reproduction in any mediumand the Ministry of Health and Medical Education
(MOHME) is responsible for fulfilling this goal through
designing and implementing national level policies.
There is at least one medical university in every province
and at the provincial level, these universities play an
important role in the provision of health services and
medical education. The Dean of a medical university is
the highest health authority at the province, reporting to
the MOHME [4]. Health services are provided by public,
quasi-public and philanthropic organizations, and a large
network of private providers. The public sector (lead by
MOHME) is the main provider of Primary Health Care
across the country and provides a large part of secon-
dary and tertiary health services [4]. The private sector
mainly provides secondary and tertiary services in urban
areas. Nearly 90% of the country’s population is covered
by health insurance, mainly public health insurance
organizations [4,5]. In spite of the high insurance coverageed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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fordable for many due to high out-of-pocket expenditures
(mainly form of co-payments) [5]. In 2011, out-of-pocket
expenditure was 60% of total health expenditures [3].
Iran’s health expenditure has been increasing rapidly
over the last decade [5]. This trend is being driven by an
ageing population, a rising prevalence of non-communi-
cable and chronic diseases, an increase in the use of health
technologies, a rise in domestic drug manufacturing and
increasing prescription and consumption of medicines
[6-8]. At the same time, the Iranian health system is being
criticized for inefficient resource allocation, providing ser-
vices without cost-effectiveness considerations, failing to
regulate the private sector and over-utilization of new
technologies [9-12]. Resource allocation decisions in Iran’s
healthcare system, have historically been based on implicit
criteria such as pre-existing service availability, afforda-
bility of the insurance organisations and providers and
political pressure [5,12]. Recently, interest in evaluating
efficiency including estimating efficiency of health care
providers [6-8] and economic evaluation of interventions
and new technologies has been growing in Iran, like
many other Asian countries [13]. The government and
MOHME have developed various strategies to improve
both the efficiency and equity of resource allocation,
including; establishing the Ministry of Welfare and Social
Security (MWSS) in 2005, incorporating all health insu-
rance organisations under MWSS with the aim of separa-
ting the health care providers/MOHME from the financiers
[5,11], and establishing the Technology Assessment Unit
within MOHME in 2007 [14]. Despite these efforts, the
extent to which evidence from economic analyses is used
to inform resource allocation in national strategic planning
and decision-making remains unclear [5,12,15].
Despite an increase in the number of economic eva-
luation studies worldwide, concern about the quality of
these studies, among other factors, has been one of the
major barriers which limit their application by policy-
makers [16-18]. In response to this policy concern,
several guidelines have been developed to assess the
quality of economic evaluation studies [1,19,20] and
many systematic review studies has been conducted in
different countries [21-25]. Arguably, these reviews focus
disproportionately on high-income countries.
While a number of economic evaluations have been
conducted in Iran, no known study has systematically
reviewed the quality of Iranian economic evaluations.
The purpose of this study was to provide a review of the
state of economic evaluation within the context of Iran.
Specifically, this review assessed whether Iranian eco-
nomic evaluation studies had been performed according
to current international standards and therefore whether
their results are likely to prove useful to policy makers.
Moreover, this study examined whether these studieswere aimed at those conditions generating a higher
burden of disease in Iran.
Methods
Literature search and study selection
A literature search was conducted independently by the
first author in December 2011 and then verified by the
second author and updated in May 2012. The search was
performed using the following international databases:
Medline/Pubmed, Embase, Web of Science, NHS
Economic Evaluation Database (EED), Econlit and Google
scholar. To identify articles published in national journals
(both in Persian and English), the Scientific Information
Database (SID) website was searched. In addition, the
references of retrieved articles were manually searched for
further papers. The search was continued until no new
articles were found. The keywords used for the literature
search were: “cost analysis”, “cost*” “economic evaluation”,
“cost-effective”, “cost-saving”, “cost-effectiveness”, “cost-
utility”, “cost-benefit”, “cost-minimisation” and “Iran*” in
the title or abstract of the articles. The full search strategy
is available in Additional file 1. Studies were included in
the review on the basis of the following inclusion criteria:
 Full economic evaluation, i.e., comparative analysis
of costs and outcomes of at least two interventions
[1] (e.g., cost minimization analysis [CMA],
cost-effectiveness analysis [CEA], cost-utility
analysis [CUA] or cost-benefit analysis [CBA]);
 Studies used primary or secondary data;
 Original articles published in international and
Iranian journals;
 Published in English and Persian (Farsi) languages;
 Applied to the Iranian context;
 Published prior to (June) 2012.
Data extraction and critical appraisal
Relevant papers were selected by screening the titles and
abstracts (first step) and entire articles (second step) ac-
cording to the inclusion criteria listed above. Screening
of articles was conducted independently by HHB and
AAK. Any disagreements about eligibility between the
authors were solved through subsequent discussion with
JSW.
Assessment of the quality of included studies was done
using a questionnaire adapted from existing guidelines,
checklists and other review articles of economic evalua-
tions [1,19,20,24,26]. The questionnaire included both
general information and economic evaluation features of
the selected articles. General information included: year
of publication, journal in which the study was published
(national or international), affiliation of the first author
(medical or non-medical), type of journal (medical, non-
medical), language (English or Persian) and geographical
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luation features of the questionnaire included method of
economic evaluation (CMA, CEA, CUA, CBA), study de-
sign, perspective (both stated and evaluated), type of sensi-
tivity analysis performed, time horizon, type of outcome
and its description, disease investigated, intervention type,
description of intervention (competitors), type of data
used (primary or secondary), types of costs included and if
they were measured and valued properly, sample size,
funding source, whether economic evaluation was the
primary study goal, whether discounting were performed
(if the costs and/or outcomes were from a study period
of >1 year) and whether generalisability of results was
discussed. Both first and second authors reviewed the se-
lected articles independently and extracted the informa-
tion into predesigned forms in Excel. Any disagreements
were solved through subsequent discussion.
To investigate whether the published studies targeted
high priority interventions, a study of the burden of
disease and injuries in Iran was used to identify high
burden health problems in the country [6]. The study,
which used methods developed by the World Health
Organization (WHO) [27] for national burden of disease
(NBD) studies, measured disease burden in terms of
disability-adjusted life years (DALYs) in the Iranian
population in 2003. In any resource constrained environ-
ment, economic evaluation studies should ideally pro-
vide evidence on cost-effectiveness of interventions to
address diseases with a high burden [2]. Therefore, ana-
lysing the disease burden and available evidence from
economic evaluation studies would provide useful infor-
mation for researchers and policy makers to establish
gaps in knowledge and priorities for future study. This
same approach has been previously used by a number of
other researchers [2,28,29].
Results
A total of 258 articles were identified by the literature
search, of which 150 articles were excluded at the initial
stage because they violated basic inclusion criteria
(Figure 1). The full-texts of 108 articles were then
reviewed and a further 78 articles were dropped because
they failed one or more inclusion criteria. The remaining
30 articles [30-59] met the inclusion criteria of the study.
Details of the reviewed studies are presented in Additional
file 2: Table S1 and Additional file 3: Table S2.
General characteristics of included studies
As can be seen from the Figure 2, the numbers of full
economic evaluation papers are scarce. Of the included
articles, 17 (57%) were published in Persian. General cha-
racteristics of the reviewed studies are presented in Table 1.
The majority of the papers (77%) were published in me-
dical journals rather than specialized health economics orhealth care sciences journals, and in twenty-two papers
(73%) the first authors had medical/clinical affiliations.
Most studies (85%) covered sub-national geographical
locations (province level), and only five studies had
national coverage (Table 1).
Economic features and quality of included studies
Table 2 reports economic and methodological features of
the selected studies and Table 3 shows the extent to which
these studies meet the recommendations for good repor-
ting of economic evaluations. Of the 30 reviewed studies,
21 studies were CEA (70%). In terms of study design, most
studies were observational (43%) following by randomized
controlled trials (RCT) (27%). Only 6 studies (20%) em-
ployed a modelling approach, which among them, type of
the model used was not specified in two studies [34,38].
While most studies did not specify their perspective
(77%), we assessed the perspective of the studies, as shown
in Table 2. The health care system/provider (77%) was the
most frequent perspective. Two studies [30,58] stated
their perspective as societal. The majority of the studies
did not perform any sensitivity analysis (73%) and those
that did so [30,32,36-39,47,58] mainly conducted one-way
sensitivity analysis (17%).
The analysis showed that 40% of the studies failed to
report their time horizon clearly. Among those that did
report the timeline, eight (27%) had time horizons of less
than one year, five (17%) between 1 to 10 years and five
over 10 years.
Among CUA studies (i.e. studies using comprehensive/
composite outcome measures such as quality-adjusted life
years [QALYs] or DALYs as their primary outcome mea-
sure) three studies used QALYs [35,37,38] and two DALYs
[39,52] as the primary effectiveness measure. Among the
three studies using QALYs, one used utility scores ob-
tained from other countries [38].
Among CEA studies (i.e. studies using intermediate
measures or natural units such as deaths prevented or
cases detected as the primary outcome measure), the ma-
jority of studies used disease specific outcome measures
such as mortality rates, number of patients detected or
number of complications, and none generic measures
such as “life years gained/saved”.
Only four CBA studies were performed in the context
of Iran [41,42,48,56]. However, after evaluating these stud-
ies closely using the criteria recommended by Drummond,
et al. [1] and Zarnke, et al. [18], these studies were not
fully measured the benefits of the interventions under
investigation. The benefits in these studies have been
defined as cost savings (mainly savings in medical costs)
without measuring and valuing the monetary values of
health gained by the intervention.
More than half (56%) of the reviewed studies focused on
curative services including surgical/medical procedures
Figure 1 Flowchart of article selection.
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(7 studies, 23%). Other studies evaluated screening/
diagnostic procedures (10 studies, 33%) and primary pre-
ventive care (2 studies, 7%). Only one study (3%) evaluated
a mode of delivery of care.
The source of cost and outcome data was clearly spe-
cified in the majority of studies (80% for costs and 97%
for outcomes). In 73% of cases, cost and outcomes data
were gathered through primary data collection. In those
studies collecting primary data, the median sample size
was 120, ranging from 30 to 1,165,169. Three studies
used a hypothetical cohort [34,39,58] and three studies
did not clearly specify their sample size [30,38,52].
Among those studies using secondary data (8 studies),
cost data were usually collected from national surveys/
reports or previous studies conducted in Iran. In fourstudies, outcomes data were obtained from studies
conducted in settings other than Iran [30,32,34,38].
All studies included direct medical costs, however only
four studies (13%) included direct non-medical costs
[32,39,56,58]. Among the two studies that adopted a so-
cietal perspective [30,58], none estimated productivity
loss and intangible costs. It is important to identify the
relevant cost items for each intervention, to measure the
resources used (in their physical units), and to value
these resources (by their prices) properly. Only 9 studies
(30%) identified all relevant costs related to each alterna-
tive intervention, considering their perspective. In most
cases, only the costs of medicine and hospitalization
were included and capital costs (such as building and
equipment) and the cost of medical supplies were not
often calculated. The data about hospitalisation costs
Figure 2 Included studies by language and publication year.
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obtained from the patients’ hospital bills. Six studies
[30,34,36,37,48,58] described clearly how they measured
and valued their cost components. Out of the 12 studies
in which the reported time horizon was more than one
year, only two studies discounted both costs and out-
comes at the same time [39,42]. A further two studies
discounted either costs [30] or outcomes [48] only. The
common discount rate utilised in the studies was 3%.
Only 5 studies [32,35,36,38,39] calculated and reported
incremental cost-effectiveness ratios (ICER). Three stu-
dies [41,42,48] reported benefit-cost ratios (BCR). Al-
though discussing the generalizability of results to the
national level or to other settings can be an important
element of an economic evaluation, the majority of
reviewed studies (87%) failed to do so. Only four studies
discussed the issue of generalizability to other settings to
some degree.
Figure 3 compares the criteria for good reporting of
economic evaluations. Based on the figure the EnglishTable 1 General characteristics of the included studies
Variable Categories N (%)
Affiliation of the first author Medical/Clinical 22 (73)
Non-medical* 8 (27)
Where journal published International 11 (37)
Regional 2 (7)
National 17 (57)
Type of journal Medical 23 (77)
Non-medical** 7 (23)
Language published English 13 (43)
Persian 17 (57)
Geographical location National 5 (17)
Sub-national 25 (83)
*Including epidemiology, health economics, health management etc.
**Including public health, health economics, health policy and management,
economics etc.language studies, which were published in international
journals, more often adhered to the recommendations
for good reporting of economic evaluations compare to
the Persian language studies.
Figure 4 shows the distribution of full economic eva-
luation studies by disease category, compared to the bur-
den of disease in the country. Based on the figure, the five
major areas of health problems in Iran are injuries (with
28% of DALYs), mental health (with 16% of DALYs), circu-
latory system diseases (with 11% of DALYs), perinatal con-
ditions (with 8% of DALYs) and musculoskeletal system
diseases (with 6% of DALYs). There are no economic
evaluation studies for the three disease categories with the
highest burdens, namely, injuries, perinatal conditions and
musculoskeletal system diseases. Moreover, only one study
investigated mental disorders, which accounted for 16% of
burden of disease in the country. The most common dis-
eases category covered by the economic evaluation studies
are “Endocrine, nutritional and metabolic diseases” (n = 5,
17%, in this group Congenital hypothyroidism was investi-
gated by four studies) and “Pregnancy, childbirth and the
puerperium” (n = 4, 13%). “Circulatory system diseases”,
“Cancers” and “Blood and blood-forming organs diseases”
were other disease groups covered by the studies (in each
group, n = 3 or 10%).
Discussion
High quality economic evaluation data on interventions
targeting high burden of diseases are important to aid
informed decision-making and resource allocation. This
study enumerates the availability of economic evaluation
studies and critically assesses the quality of those data in
the Iranian context. The findings showed that the num-
ber of economic evaluation studies in Iran is limited.
This is comparable with settings such as Bangladesh
[60], Nigeria [26], Saudi Arabia [61], Zimbabwe [62],
and lagging behind countries such as Thailand [29],
South Korea [24], India [63] and South Africa [64]. The
number of available studies remains very low compared
with high-income countries where economic evaluation
is a relatively well-established and formal part of the
policy making process [21,65]. The findings from this
review also showed that many published Iranian eco-
nomic evaluation studies did not meet current inter-
national standards and were of sub-optimal quality.
The review showed that CEA was the most frequently
published economic evaluation in Iran. The relative ease
of obtaining effectiveness data in the form of interme-
diate outcomes or natural units, and the application of
arguably more straightforward computational methods
in these types of evaluations [60] are two features that
make CEA a practical method of analysis in many set-
tings. This approach may be particularly attractive, when
collecting comprehensive outcome measures such as
Table 2 Economic features of the included studies
Feature N %
Type of economic evaluation
CEA 21 70
CUA 5 17
CBA 4 13
Study design
RCT 8 27
Quasi-experimental 3 10
Modelling 6 20
Observational (prospective, retrospective etc.) 13 43
Perspective evaluated
Societal 0 0
Government 3 10
Healthcare system/Healthcare provider 23 77
Third party 2 7
Patients 1 3
Mixed 1 3
Type of sensitivity analysis
One-way analysis 5 17
Multi-way analysis 1 3
Univariate/multivariate regression 1 3
Probabilistic analysis 1 3
Not performed 22 73
Time horizon
<= 1 year 8 27
1-10 years 5 17
Over 10 years 5 17
Not specified 12 40
Type of outcome
QALY/DALY 5 17
Intermediate (physiological, functional, etc.) 21 70
Monetary 4 13
Level of care and intervention type
Primary prevention 2 7
Curative (Surgical/Medical procedure) 10 33
Curative (Pharmaceuticals) 7 23
Diagnostic/screening (secondary prevention) 10 33
Mode of delivery of care 1 3
Type of data used
Primary data 22 73
Secondary data 4 13
Mixed 4 13
Table 2 Economic features of the included studies
(Continued)
Type of costs included
Direct medical costs 30 100
Direct non-medical costs 4 13
Indirect costs (Productivity loss) 0 0
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collect. CEA is useful in situations where outcome mea-
sures of interventions under investigation are similar.
However, since the outcome measure may differ for
different interventions, CEA can seldom be used to
make comparisons across a broad set of interventions
[1]. Taking into account this limitation, CUA or CBA
arguably provide better tools for policy makers allocating
resources across different health care programmes or
even across different sectors [1].
Considering resource constraints, it would be expected
that economic evaluations focus on interventions for dis-
eases that have a significant impact on population health.
However, the findings of the current review showed that
the majority of economic evaluation studies concentrate
on a small number of disease categories which do not in-
clude some of Iran’s major health problems. For example,Table 3 Extent to which the published evaluations met
recommendations for good reporting of economic
evaluation studies [1,20]
Criteria Number of studies fulfilling
recommendation (n/N)
%
Competing alternatives clearly
described
18/30 60
Economic evaluation as primary
objective
22/30 73
Time horizon stated 18/30 60
Perspective specified 7/30 23
All important and relevant costs
for each alternative identified
9/30 30
All included cost measured
appropriately
14/30 47
All included costs valued
appropriately
12/30 40
Sources of cost data included 24/30 80
Sources of outcome data included 29/30 97
ICER/ BCR/NPV calculated and
reported
8/30 27
Cost discounted 3/12 25
Outcome discounted 3/12 25
Sensitivity analysis performed 8/30 27
Generalisability of findings discussed 4/30 13
Funding sources disclosed 10/30 33
ICER: Incremental Cost-Effectiveness Ratio, BCR: Benefit-Cost Ratio, NPV: Net
Present Value.
Figure 3 Comparing the criteria for good reporting of economic evaluations between English and Persian language studies.
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which contribute more than 40% to burden of disease in
the country [6] and are likely to increase in the future [6],
are strongly underrepresented in the Iranian economic
evaluation literature. In addition, the findings show that
researchers have paid a great deal of attention to curative
interventions, while relatively little attention has been
given to preventive interventions and care delivery stra-
tegies. These findings are consistent with previous studies
[2,28,29]. A mismatch of economic evaluations with dis-
ease burden does not necessarily indicate inefficient re-
source allocation. It is possible that studies do not focus
on high burden illnesses because there are few effective
interventions for some health conditions. It is also possibleFigure 4 Comparison of the proportion of overall disease burden and
since 1999.that there exist a number of well-established, cost-effective
interventions for some disease categories and as such new
work in the area is not required. Difficulties in obtaining
data on the effectiveness of interventions in some areas,
such as mental disorders, can be another barrier to the
conduct of evaluations for high burden illnesses. The
interest of researchers and funding agencies could also
play a role as the majority of research in Iran is funded by
universities or other governmental research centres. Mul-
tiple criteria including equity and social justice are fre-
quently used to determining health priorities and the
burden of disease is only one of those criteria [2,28,66].
Nonetheless, we believe that comparing the priorities
reflected in the evidence regarding the burden of disease,the proportion of full economic evaluation publications in Iran
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in Iran can provide a useful starting point for discussing
future priorities for economic evaluation research.
The review indicated that the Iranian economic eva-
luation studies had low adherence to good practice criteria
for the reporting of economic evaluations and suffer from
several methodological flaws. The perspective of an eco-
nomic evaluation study is an important issue as it affects
the measurement of both costs and outcomes of interven-
tions. Yet few of the reviewed studies (only 23%) specified
their perspective. This suggests that many authors are un-
aware of the importance of the perspective adopted and
its effect on the costs and outcomes. Among the studies
which stated their perspective, many failed to include all
appropriate costs associated with their chosen perspective.
For example, two studies [30,58] stated their perspective
as societal but they didn’t measure indirect costs asso-
ciated with their interventions and those studies that had
taken a healthcare system or provider as their perspective,
failed to include capital or equipment costs and some re-
current costs (e.g. overhead costs). In the context of Iran,
obtaining data to estimate capital and overhead costs, par-
ticularly in hospital settings where most of the reviewed
studies are based, might be difficult. Moreover, some part
of these costs is usually incorporated in the inpatients and
outpatients’ costs or hospital bills, which many of the
reviewed studies included in their analysis. Using hospital
charges/bills (and also health care tariffs) in economic
evaluation have been criticised since they may not reflect
the actual costs [1,67]. In the context of Iran in particular,
hospital charges do not reflect true hospital costs due to
government subsidies for hospital services and medicines
[68]. Moreover, the effects of adverse events associated
with interventions on use of resources and outcomes were
also rarely [37,53] included in the reviewed studies. Lack
of transparency in reporting intervention costs, was an-
other important shortcoming of the reviewed studies. In
some studies [31,40,43,44,55] it becomes impossible to as-
certain what authors had actually done. Many studies
failed to describe clearly how they measured and valued
costs and did not provide details on type and quantities of
resources and their price, which limits the possibility of
replicating the evaluation in other settings.
Moreover, few studies calculated and reported ICER.
Instead of an ICER, some studies reported the average
cost-effectiveness ratio (i.e. total cost divided by total ef-
fect for the interventions being compared), which can
flaw the conclusion of the evaluation and limit direct
comparison between interventions. This is because an
average ratio implies the comparison of each alternative
with a hypothetical intervention with no costs and no
effects [69].
A major weakness of the economic evaluation studies
in the Iranian setting was the limited use of sensitivityanalysis to explore the effect of uncertainty on findings.
Only 27% of studies performed some sort of sensitivity
analysis. Sensitivity analysis helps to assess reliability of
the findings for the context of the study and can also
facilitate consideration of the generalisability of findings
to other settings [70]. Moreover, the review also showed
that very few Iranian economic evaluation studies dis-
counted costs and/or outcomes when the study period
was more than one year. None of the studies provide
justification for the discount rate used, even if that rate
was zero, and none performed a sensitivity analysis on
the rate used.
Low adherence to good practice for the conduct of eco-
nomic evaluations and the other methodological shortcom-
ings discussed above are not unique to the Iranian setting.
Systematic reviews of economic evaluation studies in some
other settings (both developed and developing countries)
have reported similar shortcomings [21,23,24,26,29,60-65].
For this reason, many countries have developed formal
and informal guidelines to standardize and improve the
quality of economic evaluation in health care [71].
Limitations of the review
Admittedly, this review may suffer from some limitations.
This study included only published literature in peer-
reviewed journals and excluded grey literature such as
government reports, pharmaceutical company reports, aca-
demic theses and conference proceedings. The inclusion of
only published literature might have introduced publica-
tion bias, since studies with positive results are more likely
to be published than studies with negative findings
[72-74]. In addition, although the database used for
searching the studies published in Persian consisted of the
majority of journals published in Iran, some journals or
studies may not have been included in this database. Fur-
thermore, as in any review study, it is difficult to rule out
selection bias or disagreement between the criteria of the
reviewers. To minimise this bias, we used pre-defined in-
clusion criteria and discussion of disagreement between
the investigators throughout of the review process.
Conclusion
The findings of this review indicate that the literature on
economic evaluation in Iran is still at an early stage and
these evaluations suffer from significant methodological
flaws. Furthermore, the review reveals that economic
evaluation studies have not focused on Iran’s most sig-
nificant health problems i.e. those contributing most to
the country’s burden of disease. Although interest in
using inputs from economic evaluation and HTA studies
has increased in Iran, evidence still points to scarce
demand for and utilisation of these inputs by policy
makers. This itself might undermine incentives to im-
prove the quality of economic evaluation studies.
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luations might benefit from the establishment of clear
national guidelines on the conduct of economic evalua-
tions. In addition, capacity building of local scientists in
the conduct of economic evaluations may be a priority
area in the future. This would require additional invest-
ment in the teaching of economic evaluation in Iranian
universities and the training of health professionals and
policy makers in the use of economic data. Moreover,
priority areas for future economic evaluation should be
established by collaboration between researchers across
disciplines, and in communication with policy makers –
taking explicit account of the national burden of disease.
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